Bone Abstracts

Introduction: Since the identification of the fact that osteoporosis represents not quite rare disease in men, its preconditions-diseases increasing the likelihood of osteoporosis in men has been intensively studied. As a result, a new direction ‘male osteoporosis’ has been established in medicine, although, there is not sufficient information on how the basic medications are selected for men; whether certain drugs have priority effect for the treatment of osteoporosis in this category of patients.

Materials and methods: Our research studied 125 male patients (aged 40–70) with osteoporosis who have been on Bivalos (Strontium Renalate) treatment for 2 years, with the standard scheme- daily 2.0 mg Ca and D3 with combined drugs (Ca D3 Nicomed Forte). Osteoporosis was diagnosed through X-ray densitometry method (Hologic-100).

On selecting Bivalos as a basic medication, its pathogenesis, its anabolic effect on osteoblasts and an antiresorptic effect caused by influencing on RANKL in OPG conditions; BMD basic index was also considered in the studied category. Despite the clinical form of the disease, average index of T-criteria in spinal ribs and hip fluctuated between 2.5S.D and 2.7S.D, which is more likely to be related to the empirically higher peek bone mass index in males.

In 56 cases out of 125 patients, hypogonadotropic hypogonadism was verified; 30 patients were with thyroid gland diseases; 15 patients with diabetes mellitus; 24 patients with rheumatoid arthritis.

Results: As a result of densitometric study after 2 year treatment, it was established that:

i) Bone mineral density in the treated patients increased, in 58% of cases reaching 7.2% in hip proximal part, while it was 4.8% in 48% of patients. Bone increase was identified in spinal ribs.

ii) Our data proves that besides antiosteoporosic effect, Bivalos has analgesic effect too which was identified in 70% of patients.

iii)All patients underwent the treatment well, without possible undesirable complications.